Head to Head Review: INmune Bio (NASDAQ:INMB) and Adaptive Biotechnologies (NASDAQ:ADPT)

INmune Bio (NASDAQ:INMB) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Valuation & Earnings

This table compares INmune Bio and Adaptive Biotechnologies’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$160,000.00	987.76	-$30.01 million	($1.92)	-4.16
Adaptive Biotechnologies	$170.28 million	2.93	-$225.25 million	($1.49)	-2.28

INmune Bio has higher earnings, but lower revenue than Adaptive Biotechnologies. INmune Bio is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

INmune Bio has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.

Insider & Institutional Ownership

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 35.2% of INmune Bio shares are held by insiders. Comparatively, 6.2% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares INmune Bio and Adaptive Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INmune Bio	-26,333.59%	-86.16%	-58.41%
Adaptive Biotechnologies	-123.24%	-56.58%	-27.45%

Analyst Ratings

This is a summary of recent recommendations and price targets for INmune Bio and Adaptive Biotechnologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	0	0	0	0	N/A
Adaptive Biotechnologies	0	2	4	0	2.67

Adaptive Biotechnologies has a consensus price target of $6.80, suggesting a potential upside of 100.59%. Given Adaptive Biotechnologies’ higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than INmune Bio.

Summary

Adaptive Biotechnologies beats INmune Bio on 9 of the 13 factors compared between the two stocks.

About INmune Bio

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.